ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Allogene Therapeutics Inc

Allogene Therapeutics Inc (ALLO)

1,785
-0,035
( -1,92% )
Aktualisiert: 18:25:33

Allogene Therapeutics Inc (ALLO) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
1,785
( -1,92% )
Gebot
1,78
Fragen
1,79
Volumen
3.165.374
1,76 Tagesbereich 1,8585
0,9842 52-Wochen-Bereich 4,46
Marktkapitalisierung
Handelsende
1,82
Handelsbeginn
1,795
Letzte Trade
100
@
1.785
Letzter Handelszeitpunkt
18:25:33
Finanzvolumen
US$ 5.677.528
VWAP
1,7936
Durchschnittliches Volumen (3 Mio.)
US$ 9.883.198
Ausgegebene Aktien
345.154.561
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-2,45
Gewinn pro Aktie (EPS)
-0,77
Erlöse (LTM)
-
Nettogewinn (LTM)
-173,76M

Über Allogene Therapeutics Inc

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engi... Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
South San Francisco, United States
Gegründet
2026
Allogene Therapeutics Inc is listed in the Healthcare sector of the NASDAQ with ticker ALLO. The last closing price for Allogene Therapeutics was US$1,82. Over the last year, Allogene Therapeutics shares have traded in a share price range of US$ 0,9842 to US$ 4,46.

Allogene Therapeutics currently has 345.154.561 shares in issue. The market capitalisation of Allogene Therapeutics is US$616,10 million. Allogene Therapeutics has a price to earnings ratio (PE ratio) of -2.45.

ALLO Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.285-13.7681159422.072.111.7582727901.91674934CS
4-0.525-22.72727272732.312.351.7573662862.0460281CS
12-0.485-21.36563876652.274.461.75104380962.34864458CS
260.36525.70422535211.424.461.29575530812.18400063CS
520.39528.41726618711.394.460.984254225771.88458529CS
156-3.905-68.62917398955.696.050.862137353362.37133466CS
260-23.015-92.802419354824.827.860.862129343614.5089428CS

ALLO - Frequently Asked Questions (FAQ)

What is the current Allogene Therapeutics Inc share price?
The current share price of Allogene Therapeutics Inc is US$ 1,785
How many Allogene Therapeutics Inc shares are in issue?
Allogene Therapeutics Inc has 345.154.561 shares in issue
What is the market cap of Allogene Therapeutics Inc?
The market capitalisation of Allogene Therapeutics Inc is USD 616,1M
What is the 1 year trading range for Allogene Therapeutics Inc share price?
Allogene Therapeutics Inc has traded in the range of US$ 0,9842 to US$ 4,46 during the past year
What is the PE ratio of Allogene Therapeutics Inc?
The price to earnings ratio of Allogene Therapeutics Inc is -2,45
What is the registered address of Allogene Therapeutics Inc?
The registered address for Allogene Therapeutics Inc is 210 East Grand Avenue, South San Francisco, California, 94080
What is the Allogene Therapeutics Inc website address?
The website address for Allogene Therapeutics Inc is allogene.com
Which industry sector does Allogene Therapeutics Inc operate in?
Allogene Therapeutics Inc operates in the Biotechnology & Life Sciences sector

ALLO Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen